Menstrual migraine: an updated review on hormonal causes, prophylaxis and treatment

Bibliography

• Stewart WF, Lipton RB, Chee E, et al. Cumulative lifetime migraine incidence in women and men. Neurology 2000;55(10):1517-23
   Google Scholar
• Granella F, Sances G, Zanferrari C, et al. Migraine without aura and reproductive life events: a clinical epidemiological study in 1300 women. Headache 1993;33(7):385-9
   Web of Science ®Google Scholar
• MacGregor EA, Brandes J, Eikermann A, et al. Impact of migraine on patients and their families: the Migraine And Zolmitriptan Evaluation (MAZE) survey – Phase III. Curr Med Res Opin 2004;20(7):1143-50
   PubMed Web of Science ®Google Scholar
• Silberstein SD, Merriam GR. Estrogens, progestins, and headache. Neurology 1991;41:775-93
   Google Scholar
• Goldstein M, Chen TC. The epidemiology of disabling headache. In: Critchley M, editor. Advances in neurology. Lippincott Williams & Wilkins, Hagerstown, MD; 1982. p. 377-90
   Google Scholar
• Lipton RB, Stewart WF. Migraine in the United States: a review of the epidemiology and health care use. Neurology 1993;43(6 Suppl 3):S6-10
   PubMed Web of Science ®Google Scholar
• Nett R, Landy S, Shackelford S, et al. Pain-free efficacy after treatment with sumatriptan in the mild pain phase of menstrually associated migraine. Obstet Gynecol 2003;102:835-42
   PubMed Web of Science ®Google Scholar
• Landy S, Savani N, Shackelford S, et al. Efficacy and tolerability of sumatriptan tablets administered during the mild-pain phase of menstrually associated migraine. Int J Clin Pract 2004;58:913-19
   PubMed Web of Science ®Google Scholar
• Schreiber C, Cady R. Diagnosis of menstrual headache and an open-label study among those with previously undiagnosed menstrually related migraine to evaluate the efficacy of sumatriptan 100 mg. Clin Ther 2007;29(Suppl):2511-19
   PubMedGoogle Scholar
• Facchinetti F, Allais G, Nappi R, et al. Sumatriptan (50 mg tablets versus 25 mg suppositories) in the acute treatment of menstrually related migraine and oral contraceptive-induced menstrual migraine: a pilot study. Gynecol Endocrinol 2010;26:773-9
   PubMed Web of Science ®Google Scholar
• Mannix LK, Martin VT, Cady RK, et al. Combination treatment for menstrual migraine and dysmenorrhea using sumatriptan-naproxen: two randomized controlled trials. Obstet Gynecol 2009;114:106-13
   PubMed Web of Science ®Google Scholar
• Silberstein S, Massiou H, Le Jeunne C, et al. Rizatriptan in the treatment of menstrual migraine. Obstet Gynecol 2000;237-42
   Google Scholar
• Silberstein S, Massiou H, McCarroll K, et al. Further evaluation of rizatriptan in menstrual migraine: retrospective analysis of long-term data. Headache 2002;42:917-23
   PubMed Web of Science ®Google Scholar
• Nett R, Mannix L, Mueller L, et al. Rizatriptan efficacy in ICHD-II pure menstrual migraine and menstrually related migraine. Headache 2008;48:1194-201
   PubMed Web of Science ®Google Scholar
• Martin V, Cady R, Mauskop A, et al. Efficacy of rizatriptan for menstrual migraine in an early intervention model: a prospective subgroup analysis of the rizatriptan TAME (Treat A Migraine Early) studies. Headache 2008;48:226-35
   PubMed Web of Science ®Google Scholar
• Savi L, Omboni S, Lisotto C, et al. Efficacy of frovatriptan in the acute treatment of menstrually related migraine: analysis of a double-blind, randomized, cross-over, multicenter, Italian, comparative study versus rizatriptan. J Headache Pain 2011;12:609-15
   PubMed Web of Science ®Google Scholar
• Allais G, Bussone G, Airola G, et al. Oral contraceptive-induced menstrual migraine. Clinical aspects and response to frovatriptan. Neurol Sci 2008;29(Suppl 1):S186-90
   PubMedGoogle Scholar
• Allais G, Tullo V, Benedetto C, et al. Efficacy of frovatriptan in the acute treatment of. menstrually related migraine: analysis of a double-blind, randomized, multicenter, Italian, comparative study versus zolmitriptan. Neurol Sci 2011;32(Suppl 1):S99-S104
   PubMedGoogle Scholar
• Bartolini M, Giamberardino M, Lisotto C, et al. Frovatriptan versus almotriptan for acute treatment of menstrual migraine: analysis of a double-blind, randomized, cross-over, multicenter, Italian, comparative study. J Headache Pain 2012;13:401-6
   PubMed Web of Science ®Google Scholar
• Newman L, Mannix LK, Landy S, et al. Naratriptan as short-term prophylaxis of menstrually associated migraine: a randomized, double-blind, placebo-controlled study. Headache 2001;41:248-56
   PubMed Web of Science ®Google Scholar
• Massiou H, Jamin C, Hinzelin G, et al. French Naramig Collaborative Study Group. Efficacy of oral naratriptan in the treatment of menstrually related migraine. Eur J Neurol 2005;12:774-81
   PubMed Web of Science ®Google Scholar
• Loder E, Silberstein S, Abu-Shakra S, et al. Efficacy and tolerability of oral zolmitriptan in menstrually associated migraine: a randomized, prospective, parallel-group, double-blind, placebo-controlled study. Headache 2004;44:120-30
   PubMed Web of Science ®Google Scholar
• Allais G, Acuto G, Cabarrocas X, et al. Efficacy and tolerability of almotriptan versus zolmitriptan for the acute treatment of menstrual migraine. Neurol Sci 2006;27(Suppl 2):S193-7
   PubMed Web of Science ®Google Scholar
• Tuchman M, Hee A, Emeribe U, et al. Efficacy and tolerability of zolmitriptan oral tablet in the acute treatment of menstrual migraine. CNS Drugs 2006;20:1019-26
   PubMed Web of Science ®Google Scholar
• Diamond M, Cady R, Mao L, et al. Characteristics of migraine attacks and responses to almotriptan treatment: a comparison of menstrually related and nonmenstrually related migraines. Headache 2008;48:248-58
   PubMed Web of Science ®Google Scholar
• Allais G, Bussone G, D’Andrea G, et al. Almotriptan 12.5 mg in menstrually related migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia 2011;31:144-51
   PubMed Web of Science ®Google Scholar
• D’Alessandro R, Gamberini G, Lozito A, et al. Menstrual migraine: intermittent prophylaxis with a time-relase pharmacological formulation of dihydroergotamine. Cephalagia 1983;3(Suppl 1):156-8
   PubMedGoogle Scholar
• Allais G, Bussone G, De Lorenzo C, et al. Naproxen sodium in short-term prophylaxis of pure menstrual migraine: pathophysiological and clinical considerations. Neurol Sci 2007;28(Suppl 2):S225-8
   PubMedGoogle Scholar
• Newman LC, Lipton RB, Lay CL, et al. A pilot study of oral sumatriptan as intermittent prophylaxis of menstruation-related migraine. Neurology 1998(51):307-9
   Google Scholar
• Tuchman MM, Hee A, Emeribe U, et al. Oral zolmitriptan in the short-term prevention of menstrual migraine: a randomized, placebo-controlled study. CNS Drugs 2008;22:877-86
   PubMed Web of Science ®Google Scholar
• Moschiano F, Allais G, Grazzi L, et al. Naratriptan in the short-term prophylaxis of pure menstrual migraine. Neurol Sci 2005;26(Suppl 2):S162-6
   PubMedGoogle Scholar
• Mannix LK, Savani N, Landy S, et al. Efficacy and tolerability of naratriptan for short-term prevention of menstrually related migraine: data from two randomized, double-blind, placebo-controlled studies. Headache 2007;47:1037-49
   PubMed Web of Science ®Google Scholar
• Silberstein SD, Elkind AH, Schreiber C, et al. A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine. Neurology 2004;63:261-9
   PubMed Web of Science ®Google Scholar
• Brandes JL, Poole A, Kallela M, et al. Short-term frovatriptan for the prevention of difficult-to-treat menstrual migraine attacks. Cephalalgia 2009;29:1133-48
   PubMed Web of Science ®Google Scholar
• Guidotti M, Mauri M, Barrilà C, et al. Frovatriptan vs transdermal estrogens or naproxen sodium for the prophylaxis of menstrual migraine. J Headache Pain 2007;8:283-8
   PubMedGoogle Scholar
• Wade A, Pawsey S, Whale H, et al. Pharmacokinetics of two 6-day frovatriptan dosing regimens used for the short-term prevention of menstrual migraine: A phase I, randomized, double-blind, placebo-controlled, two-period crossover, single-centre study in healthy female volunteers. Clin Drug Investig 2009;29:325-37
   PubMed Web of Science ®Google Scholar
• Facchinetti F, Sances G, Borella P, et al. Magnesium prophylaxis of menstrual migraine: effects on intracellular magnesium. Headache 1991;31(5):298-301
   PubMedGoogle Scholar
• De Lignieres B, Vincens M, Mauvais-Jarvis P, et al. Prevention of menstrual migraine by percutaneous estradiol. Br Med J(Clin Res Ed) 1986;293(6561):1540
   PubMedGoogle Scholar
• Pfaffenrath V. Efficacy and safety of percutaneous estradiol vs placebo in menstrual migraine. Cephalalgia 1993;13(Suppl 13):244
   Google Scholar
• LaGuardia KD, Fisher AC, Bainbridge JD, et al. Suppression of estrogen-withdrawal headache with extended transdermal contraception. Fertil Steril 2005;83(6):1875-7
   PubMedGoogle Scholar
• MacGregor EA, Frith A, Ellis J, et al. Prevention of menstrual attacks of migraine: a double-blind placebo-controlled crossover study. Neurology 2006;67:2159-63
   PubMed Web of Science ®Google Scholar
• Coffee AL, Sulak PJ, Hill AJ, et al. Extended cycle combined oral contraceptives and prophylactic frovatriptan during the hormone-free interval in women with menstrual-related migraines. J Womens Health (Larchmt) 2014;23(4):310-17
   PubMedGoogle Scholar
• Casolla B, Lionetto L, Candela S, et al. Treatment of perimenstrual migraine with triptans: an update. Curr Pain Headache Rep 2012;16(5):445-51
   PubMed Web of Science ®Google Scholar
• Hu Y, Guan X, Fan L, et al. Triptans in prevention of menstrual migraine: a systematic review with meta-analysis. Headache Pain 2013;14(1):7
   PubMedGoogle Scholar
• Negro A, Napoletano F, Lionetto L, et al. Treatment of menstrual migraine: utility of control of related mood disturbances. Expert Rev Neurother 2014;14(5):493-502
   PubMed Web of Science ®Google Scholar